# US 2024/0002855 A1 · Nucleic Acid Molecule Binding to YB-1 Protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002855 A1
- Document ID: US20240002855A1
- Status: Published application
- Kind: A1
- Application number: 18/254,616
- Filed: 2021-11-26
- Published: 2024-01-04
- Earliest claimed: 2020-11-27
- Assignees: Center for Excellence In Molecular Cell Science, Chinese Academy of Sciences
- Applicants: Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences
- Inventors: JingYi Hui; JinZhu Wang; Hong Zhu
- Web page: https://patentgrep.com/patent/US20240002855A1

## CPC

- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 35/00: Antineoplastic agents
- C07K 1/14: Extraction; Separation; Purification
- C07K 14/82: Translation products from oncogenes
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 15/09: Recombinant DNA-technology
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 15/85: for animal cells
- G01N 33/575: for cancer
- C12N 2310/321: 2'-O-R Modification
- C12N 2320/33: Alteration of splicing
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided are a nucleic acid molecule binding to an YB-1 protein and an application thereof in diagnosis, prevention and treatment of cancers. The nucleic acid molecule comprises a sequence selected from the group consisting of: (1) a nucleic acid sequence shown in N1N2N3N4AN5CN6N7N8 (SEQ ID NO: 1), wherein N1 is C, G, U, or none, N2 is A, G, U, or none, N3 is C, G, U, or none, N4 is C, G, U, or none, N5 is C or U, and each of N6, N7 and N8 is independently C, G, U, or none; and (2) a complementary sequence of (1).

## Claims

### Claim 1

An RNA oligonucleotide targeting YB-1 protein, wherein the RNA oligonucleotide comprises a nucleotide sequence selected from the group consisting of:
(1) a nucleotide sequence shown by N1N2N3N4AN5CN6N7N8 (SEQ ID NO: 1), wherein N1 is C, G, U or null, N2 is A, G, U or null, N3 is C, G, U or null, N4 is C or G, N5 is C or U, and each of N6, N7 and N8 is independently C, G, U or null, and
(2) a complementary sequence of (1).

### Claim 2 (depends on 1)

The RNA oligonucleotide according to claim 1, wherein:
the RNA oligonucleotide is 3-50 nts or 3-30 nts in length, or
N1 is C, G, U or null, N2 is A, G, U or null, N3 is C, G, U or null, N4 is C or G, N5 is C or U, and each of N6, N7 and N8 is independently C, G, U or null, or
N1 is C, U or null, N2 is A, G or null, N3 is C or null, N4 is C or G, N5 is C or U, N6 is G, U or null, N7 is C, G or null, and N8 is C, G, U or null, or
N1 is U or null, N2 is G or null, N3 is C or null, N4 is C or G, N5 is C or U, N6 is U or null, N7 is G or null, and N8 is C or null, or
the RNA oligonucleotide comprises two or more copies of the nucleotide sequences which are optionally linked by a linker sequence comprising 1-10 nucleotides selected from the group consisting of A, U, G, and C, or
at least one nucleotide in the RNA oligonucleotide is a modified nucleotide for stabilization of the oligonucleotide.

### Claim 3 (depends on 1)

A protein-RNA complex comprising the RNA oligonucleotide according to claim 1 and an RNA binding protein bound thereto.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising the RNA oligonucleotide according to claim 1 and/or a protein-RNA complex comprising the RNA oligonucleotide and an RNA binding protein bound thereto, and a pharmaceutically acceptable excipient.

### Claim 5 (depends on 1)

A method for isolating or purifying a protein, comprising: incubating a candidate protein with the RNA oligonucleotide according to claim 1 which is labeled, and isolating or purifying the protein bound to the RNA oligonucleotide using the label.

### Claim 6 (depends on 1)

An in vitro method for mediating a specific alteration of a target protein in cells, comprising the steps of:
(1) contacting the cells with the RNA oligonucleotide according to claim 1, and
(2) mediating the specific alteration of a target protein by the RNA oligonucleotide, directing the RNA oligonucleotide to the protein with which it interacts.

### Claim 7 (depends on 1)

A method for decreasing activity or amount of YB-1 protein, regulating mRNA alternative splicing, regulating miRNA biogenesis, regulating DNA damage, regulating RNA transcription, regulating RNA degradation, regulating protein translation, or regulating non-coding RNA processing, wherein the method comprises the step of contacting the RNA oligonucleotide according to claim 1 with the YB-1 protein in cells.

### Claim at position 8

8-10. (canceled)

### Claim 11 (depends on 2)

The RNA oligonucleotide according to claim 2, wherein:
the RNA oligonucleotide comprises a sequence selected from the group consisting of: GUCAUCUU, GUCACCUU, GCCAUCUG, UGCAUCCU, ACCAUCUG, CACCAUCG, CACCAUC, UCAUCU, UCACCU, CCAUCU, GCAUCC, CCAUCU, ACCAUC, UYAUC, UCACC, CAUC, CACC, GAUC, and AUC; and/or
the modification is selected from the group consisting of 2′-O-methyl, 2′-O-methoxyethyl, 5′-methyl, phosphorothioate and nucleotide analogues.

### Claim 12 (depends on 3)

The protein-RNA complex according to claim 3, wherein:
the RNA binding protein is an YB-1 protein; and/or
the RNA oligonucleotides are 3-50 nts or 3-30 nts in length; and/or
at least one nucleotide in the RNA oligonucleotide is a modified nucleotide by for stabilization of the oligonucleotide; and/or
in SEQ ID NO:1, N1 is C, G, U or null, N2 is A, G, U or null, N3 is C, G, U or null, N4 is C or G, N5 is C or U, and each of N6, N7 and N8 is independently C, G, U or null; or N1 is C, U or null, N2 is A, G or null, N3 is C or null, N4 is C or G, N5 is C or U, N6 is G, U or null, N7 is C, G or null, and N8 is C, G, U or null; or N1 is U or null, N2 is G or null, N3 is C or null, N4 is C or G, N5 is C or U, N6 is U or null, N7 is G or null, and N8 is C or null; and/or
the RNA oligonucleotide comprises two or more copies of the nucleotide sequences which are optionally separated by a linker sequence comprising 1-10 nucleotides selected from the group consisting of A, U, G, and C.

### Claim 13 (depends on 12)

The protein-RNA complex according to claim 12, wherein:
the RNA oligonucleotide comprises a sequence selected from the group consisting of: GUCAUCUU, GUCACCUU, GCCAUCUG, UGCAUCCU, ACCAUCUG, CACCAUCG, CACCAUC, UCAUCU, UCACCU, CCAUCU, GCAUCC, CCAUCU, ACCAUC, UYAUC, UCACC, CAUC, CACC, GAUC, and AUC; and/or
the modification is selected from the group consisting of 2′-O-methyl, 2′-O-methoxyethyl, 5′-methyl, phosphorothioate and nucleotide analogues.

### Claim 14 (depends on 4)

The pharmaceutical composition according to claim 4, wherein:
the RNA binding protein is an YB-1 protein; and/or
the RNA oligonucleotides are 3-50 nts or 3-30 nts in length; and/or
at least one nucleotide in the RNA oligonucleotide is a modified nucleotide by for stabilization of the oligonucleotide; and/or
in SEQ ID NO:1, N1 is C, G, U or null, N2 is A, G, U or null, N3 is C, G, U or null, N4 is C or G, N5 is C or U, and each of N6, N7 and N8 is independently C, G, U or null; or N1 is C, U or null, N2 is A, G or null, N3 is C or null, N4 is C or G, N5 is C or U, N6 is G, U or null, N7 is C, G or null, and N8 is C, G, U or null; or N1 is U or null, N2 is G or null, N3 is C or null, N4 is C or G, N5 is C or U, N6 is U or null, N7 is G or null, and N8 is C or null; and/or
the RNA oligonucleotide comprises two or more copies of the nucleotide sequences which are optionally separated by a linker sequence comprising 1-10 nucleotides selected from the group consisting of A, U, G, and C.

### Claim 15 (depends on 14)

The pharmaceutical composition according to claim 14, wherein:
the RNA oligonucleotide comprises a sequence selected from the group consisting of:
GUCAUCUU, GUCACCUU, GCCAUCUG, UGCAUCCU, ACCAUCUG, CACCAUCG, CACCAUC, UCAUCU, UCACCU, CCAUCU, GCAUCC, CCAUCU, ACCAUC, UYAUC, UCACC, CAUC, CACC, GAUC, and AUC; and/or
the modification is selected from the group consisting of 2′-O-methyl, 2′-O-methoxyethyl, 5′-methyl, phosphorothioate and nucleotide analogues.

### Claim 16 (depends on 5)

The method according to claim 5, wherein the label is biotin and the isolating or purifying comprises contacting the incubation mixture with a solid phase conjugated with streptavidin.

### Claim 17 (depends on 5)

The method according to claim 5, wherein:
the RNA binding protein is a YB-1 protein; and/or
the RNA oligonucleotides are 3-50 nts or 3-30 nts in length; and/or
at least one nucleotide in the RNA oligonucleotide is a modified nucleotide by for stabilization of the oligonucleotide; and/or
in SEQ ID NO:1, N1 is C, G, U or null, N2 is A, G, U or null, N3 is C, G, U or null, N4 is C or G, N5 is C or U, and each of N6, N7 and N8 is independently C, G, U or null; or N1 is C, U or null, N2 is A, G or null, N3 is C or null, N4 is C or G, N5 is C or U, N6 is G, U or null, N7 is C, G or null, and N8 is C, G, U or null; or N1 is U or null, N2 is G or null, N3 is C or null, N4 is C or G, N5 is C or U, N6 is U or null, N7 is G or null, and N8 is C or null; and/or
the RNA oligonucleotide comprises two or more copies of the nucleotide sequences which are optionally separated by a linker sequence comprising 1-10 nucleotides selected from the group consisting of A, U, G, and C.

### Claim 18 (depends on 17)

The method according to claim 17, wherein:
the RNA oligonucleotide comprises a sequence selected from the group consisting of:
GUCAUCUU, GUCACCUU, GCCAUCUG, UGCAUCCU, ACCAUCUG, CACCAUCG, CACCAUC, UCAUCU, UCACCU, CCAUCU, GCAUCC, CCAUCU, ACCAUC, UYAUC, UCACC, CAUC, CACC, GAUC, and AUC; and/or
the modification is selected from the group consisting of 2′-O-methyl, 2′-O-methoxyethyl, 5′-methyl, nucleotide analogue and phosphorothioate.

### Claim 19 (depends on 6)

The method according to claim 6, wherein:
the protein is an RNA binding protein, and/or
the protein alteration is inhibition of protein activity, and/or
the contacting includes introducing the RNA oligonucleotide into cells which are capable of generating the specific alteration of a target protein; and/or
the RNA binding protein is a YB-1 protein; and/or
the RNA oligonucleotides are 3-50 nts or 3-30 nts in length; and/or
at least one nucleotide in the RNA oligonucleotide is a modified nucleotide by for stabilization of the oligonucleotide; and/or
the RNA oligonucleotide comprises a sequence selected from the group consisting of: GUCAUCUU, GUCACCUU, GCCAUCUG, UGCAUCCU, ACCAUCUG, CACCAUCG, CACCAUC, UCAUCU, UCACCU, CCAUCU, GCAUCC, CCAUCU, ACCAUC, UYAUC, UCACC, CAUC, CACC, GAUC, and AUC.

### Claim 20 (depends on 7)

The method according to claim 7, wherein:
the protein is an RNA binding protein, and/or
the protein alteration is inhibition of protein activity, and/or
the contacting includes introducing the RNA oligonucleotide into cells which are capable of generating the specific alteration of a target protein; and/or
the RNA binding protein is a YB-1 protein; and/or
the RNA oligonucleotides are 3-50 nts or 3-30 nts in length; and/or at least one nucleotide in the RNA oligonucleotide is a modified nucleotide by for stabilization of the oligonucleotide; and/or
the RNA oligonucleotide comprises a sequence selected from the group consisting of: GUCAUCUU, GUCACCUU, GCCAUCUG, UGCAUCCU, ACCAUCUG, CACCAUCG, CACCAUC, UCAUCU, UCACCU, CCAUCU, GCAUCC, CCAUCU, ACCAUC, UYAUC, UCACC, CAUC, CACC, GAUC, and AUC; and/or
the YB-1 protein-related disease or disorder comprises a YB-1 protein-related tumor

### Claim 21 (depends on 1)

A method for preventing or treating a YB-1 protein-related disease or disorder, inhibiting tumor cell proliferation, malignant transformation or metastasis, improving drug resistance, or inhibiting epithelial-mesenchymal transition (EMT), comprising administering to a subject in need thereof an effective amount of the RNA oligonucleotide according to claim 1 and/or a protein-RNA complex comprising the RNA oligonucleotide and an RNA binding protein bound thereto, or a pharmaceutical composition comprising the RNA oligonucleotide and/or the protein-RNA complex.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the YB-1 protein-related disease or disorder comprises a YB-1 protein-related tumor.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the YB-1 protein-related tumor is lung cancer, breast cancer, neurospoagioma, glioma, cervical cancer, liver cancer, head and neck cancer, prostate cancer, lymphoma, bladder cancer, pancreatic cancer, hepatobiliary cancer, colorectal cancer, or osteosarcoma.
